Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine

On the eve of World AIDS Day (December 1) Johnson & Johnson (www.JnJ.com) announced that its Janssen Pharmaceutical Companies (www.Janssen.com) together with a consortium of global partners have initiated the first efficacy study for an investigational mosaic HIV-1 preventive vaccine. The Bill & Melinda Gates Foundation (www.GatesFoundation.org) and National Institutes of Health are joining forces… […]http://feedproxy.google.com/~r/Appa-sourceTheAfric...